CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE: The TWIN Study
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
In Brief Purpose: The real-life LUMIERE study on patients with wet age-related macular degeneration treated with intravitreal ranibizumab in 2006 to 2009 showed that failure to follow recommendations was associated with lower efficacy than had been observed in the development phase. The TWIN Study reviewed the situation in 2010 to 2011. Methods: Retrospective, descriptive purely observational study of data acquired after 12 months of treatment with intravitreal ranibizumab. Results: In 881 patients (68% women, mean age, 79 years) treated by 21 ophthalmologists, the mean gain in visual acuity was +4.3 ± 15.4 letters (up from 3.2 ± 14.8 in 2006–2009; NS). Significant improvements were documented in the mean interval between diagnosis and treatment initiation (down from 12.6 ± 26.4–7.7 ± 10.9 days; P < 0.001), and in the percentage of patients who received a full course of induction treatment (56.6 vs. 39.6%; P < 0.001). After induction, hardly any patients were monitored every month as recommended, although retreatment was more assiduous (5.6 ± 2.3 vs. 5.1 ± 2.1 injections; P < 0.001). Conclusion: Despite improvements in key parameters, the effectiveness of intravitreal ranibizumab is still compromised by poor compliance with the guidelines, especially the frequency of postinduction monitoring that is now the most important determinant of successful treatment. Ranibizumab in daily clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration
Gupta, O. P., Shienbaum, G., Patel, A. H., Fecarotta, C., Kaiser, R. S., & Regillo, C. D. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.032 · Cited by 272
Cited by
Mehta, H., Tufail, A., Daien, V., Lee, A. Y., Nguyen, V., Ozturk, M., Barthelmes, D., & Gillies, M. C. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.12.002 · Cited by 265
Ciulla, T. A., Huang, F., Westby, K., Williams, D. F., Zaveri, S., & Patel, S. C. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.01.006 · Cited by 115
Innovative therapies for neovascular age-related macular degeneration
Al-Khersan, H., Hussain, R. M., Ciulla, T. A., & Dugel, P. U. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1636031 · Cited by 114
Korobelnik, J.-F., Delcourt, C., Creuzot-Garcher, C., Melaine, A., Chassetuillier, J., Lejeune, A., Bénard, S., & Dupont-Benjamin, L. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.1971416 · Cited by 9
Metadata
- Authors
- Souied, E. H., Oubraham, H., Mimoun, G., Cohen, S. Y., Quere, S., & Derveloy, A.
- Venue
- Retina
- Published
- 2015-09
- Volume
- 35
- Issue
- 9
- Pages
- 1743-1749
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W4248752180
- Cited by
- 59
- References
- 2
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE: The TWIN Study. https://app.cochat.ai/papers/10.1097/iae.0000000000000548
- The paper
- Souied, E. H., Oubraham, H., Mimoun, G., Cohen, S. Y., Quere, S., & Derveloy, A. (2015). CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE: The TWIN Study. Retina. https://doi.org/10.1097/iae.0000000000000548
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.